A Mab A Case Study In Bioprocess Development Online

2. Upstream Process Development: Cell Line and Culture Optimization

Analytical validation was performed in parallel with process development to ensure that process changes did not alter the mAb’s quality profile. Quality Attribute Analytical Method Target Acceptance Criteria Size Exclusion HPLC (SE-HPLC) Identity & Intact Mass Liquid Chromatography-Mass Spectrometry (LC-MS) Matches reference standard Charge Variants Capillary Isoelectric Focusing (cIEF) Glycan Profiling Hydrophilic Interaction Liquid Chromatography (HILIC) Consistent G0F, G1F, G2F distribution Host Cell Protein (HCP) Enzyme-Linked Immunosorbent Assay (ELISA) Residual Protein A Sandwich ELISA

The FDA approved A Mab with – a testament to robust bioprocess development.

Produced by a collaboration of major biopharmaceutical companies—including Amgen, Genentech, Eli Lilly, GlaxoSmithKline, MedImmune, Pfizer, and Roche—this hypothetical molecule case study served as a blueprint for translating abstract regulatory concepts from the International Council for Harmonisation ( ICH Guidelines ) into concrete engineering and manufacturing workflows. Decades later, the A-Mab framework remains a foundational reference for bioprocess scientists working to balance speed, cost, and regulatory compliance. Core Principles of Quality by Design (QbD) A Mab A Case Study In Bioprocess Development

The was defined such that any combination within ranges (e.g., Protein A elution pH 3.6–4.0, polishing flow rate 150–250 cm/h) yielded CQA compliance.

The primary article you are looking for is titled "A-Mab: A Case Study in Bioprocess Development," published on October 30, 2009, by the CMC Biotech Working Group International Society for Pharmaceutical Engineering (ISPE)

Low pH hold (pH 3.6 for 60 minutes) was used. But with A Mab’s sensitivity, they optimized to pH 3.7 for exactly 30 minutes – no longer, no shorter. Validation showed >4 log reduction of model virus (xMuLV). The primary article you are looking for is

Regulatory guidance for process validation is provided by bodies like the FDA and EMA, with key frameworks coming from the . ICH guidelines such as Q8 (Quality by Design), Q9 (Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Drug Substance Development) are foundational. The FDA's guidance on PV outlines a three-stage approach: Stage 1 (Process Design), Stage 2 (Process Qualification), and Stage 3 (Continued Process Verification). For Process Performance Qualification (PPQ) , agencies typically require data from three consecutive commercial-scale batches to demonstrate consistent performance.

Once the mAb is produced, it must be isolated and purified from the cell culture. Contentstack A–Mab: A Case Study in Bioprocess Development - ISPE 30 Oct 2009 —

Once a lead clone is selected, the work to refine its chemical and physical environment begins. A central challenge is maintaining while managing the buildup of toxic waste products like lactate and ammonia. A key strategy for A-mAb is the transition from a traditional fed-batch process to an intensified perfusion method. In a case study with a similar mAb for osteoporosis treatment, Enzene Biosciences documented the dramatic benefits of this shift. By implementing an intensified perfusion process, productivity jumped from 15g in a 5L fed-batch to 48g in a 2L perfusion and an astonishing 730g in a 30L perfusion system. This highlights the potential of process intensification to unlock orders-of-magnitude gains in yield. By implementing an intensified perfusion process

The development of bioprocesses for the production of monoclonal antibodies (mAbs) has revolutionized the field of biotechnology. One such case study is the development of a bioprocess for the production of a monoclonal antibody, referred to as "A Mab". This article will provide an in-depth look at the challenges faced during the development of the A Mab bioprocess, the strategies employed to overcome these challenges, and the lessons learned from this case study.

The upstream portion of the A-Mab case study focuses on managing biological variability during cell culture. Using Chinese Hamster Ovary (CHO) cell lines, developers leverage multivariate analysis to establish clear boundaries for cell growth and protein expression.